Sangamo BioSciences Presentats Positive Data from Alzheimer's Disease Treatment
November 15, 2013 at 07:02 AM EST
Sangamo BioSciences (NASDAQ: SGMO ) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease (AD). This novel product was developed by Ceregene, Inc., which was
